PHARMACOKINETICS OF IN-111 T101 (ANTI-CD5) MONOCLONAL-ANTIBODY IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA

The pharmacokinetics of In-111 T101, an anti-CD5 murine monoclonal ant ibody, were studied in 11 patients. The T101 was labeled with In-111 u sing a modification of the mixed anhydride method. Each patient receiv ed the content of one kit (5 mCi and 1 mg) injected alone (five patien ts) or mixed and co-injected with 9 mg (three patients) or 49 mg (thre e patients) of unlabeled T101. Dose dependent differences in biodistri bution in normal organs were observed. The liver, spleen and bone marr ow were sites of prominent accumulation at all dose levels. Higher dos es of T101 resulted in less accumulation of In-111 in these sites and prolongation of the blood pool retention. Visualization of tumors was seen at all dose levels and did not appear to be dose dependent. These studies indicate that dose is an important determinant of T101 pharma cokinetics.